Results 171 to 180 of about 5,288 (183)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

Ca-A Cancer Journal for Clinicians, 2011
Kiran K Turaga
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

The adenosine pathway in immuno-oncology

Nature Reviews Clinical Oncology, 2020
Bertrand Allard, Laurence Buisseret, John Stagg   +2 more
exaly  

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Nature Reviews Clinical Oncology, 2016
Fausto Castagnetti, Michele Baccarani
exaly  

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Biochemistry of Peroxynitrite and Protein Tyrosine Nitration

Chemical Reviews, 2018
Gerardo Ferrer-Sueta, Madia Trujillo, Silvina Bartesaghi   +2 more
exaly  

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Nature Reviews Clinical Oncology, 2014
William Pao, Lecia V Sequist
exaly